IgG Responses to Porins and Lipopolysaccharide within an Outer Membrane-Based Vaccine against Nontyphoidal <italic toggle="yes">Salmonella</italic> Develop at Discordant Rates
Anna E. Schager,
C. Coral Dominguez-Medina,
Francesca Necchi,
Francesca Micoli,
Yun Shan Goh,
Margaret Goodall,
Adriana Flores-Langarica,
Saeeda Bobat,
Charlotte N. L. Cook,
Melissa Arcuri,
Arianna Marini,
Lloyd D. W. King,
Faye C. Morris,
Graham Anderson,
Kai-Michael Toellner,
Ian R. Henderson,
Constantino López-Macías,
Calman A. MacLennan,
Adam F. Cunningham
Affiliations
Anna E. Schager
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
C. Coral Dominguez-Medina
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Francesca Necchi
GSK Vaccines Institute for Global Health, Siena, Italy
Francesca Micoli
GSK Vaccines Institute for Global Health, Siena, Italy
Yun Shan Goh
GSK Vaccines Institute for Global Health, Siena, Italy
Margaret Goodall
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Adriana Flores-Langarica
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Saeeda Bobat
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Charlotte N. L. Cook
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Melissa Arcuri
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Arianna Marini
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Lloyd D. W. King
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Faye C. Morris
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Graham Anderson
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Kai-Michael Toellner
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Ian R. Henderson
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
Constantino López-Macías
Medical Research Unit on Immunochemistry, National Medical Center “SigloXXI,” Specialties Hospital, Mexican Institute for Social Security (IMSS), Mexico City, Mexico
Calman A. MacLennan
GSK Vaccines Institute for Global Health, Siena, Italy
Adam F. Cunningham
Institute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom
ABSTRACT Antibodies acquired after vaccination or natural infection with Gram-negative bacteria, such as invasive Salmonella enterica serovar Typhimurium, can protect against disease. Immunization with naturally shed outer membrane vesicles from Gram-negative bacteria is being studied for its potential to protect against many infections, since antigens within vesicles maintain their natural conformation and orientation. Shedding can be enhanced through genetic modification, and the resulting particles, generalized modules for membrane antigens (GMMA), not only offer potential as vaccines but also can facilitate the study of B-cell responses to bacterial antigens. Here we show that the response to immunization with GMMA from S. Typhimurium (STmGMMA) provides B-cell-dependent protection and induces antibodies to two immunodominant antigens, lipopolysaccharide (LPS) and porins. Antibodies to LPS O antigen (O-Ag) markedly enhance protection in the spleen, but this effect is less marked in the liver. Strikingly, IgG responses to LPS and porins develop with distinct kinetics. In the first week after immunization, there is a dramatic T-cell-independent B1b-cell-associated induction of all IgG isotypes, except IgG1, to porins but not to LPS. In contrast, production of IgG1 to either antigen was delayed and T cell dependent. Nevertheless, after 1 month, cells in the bone marrow secreting IgG against porins or LPS were present at a similar frequency. Unexpectedly, immunization with O-Ag-deficient STmGMMA did not substantially enhance the anti-porin response. Therefore, IgG switching to all antigens does not develop synchronously within the same complex and so the rate of IgG switching to a single component does not necessarily reflect its frequency within the antigenic complex. IMPORTANCE Vaccines save millions of lives, yet for some infections there are none. This includes some types of Salmonella infections, killing hundreds of thousands of people annually. We show how a new type of vaccine, called GMMA, that is made from blebs shed from the Salmonella cell wall, works to protect against infection in mice by inducing host proteins (antibodies) specifically recognizing bacterial components (antigens). The rate of development of IgG antibody to antigens within GMMA occurred with different kinetics. However, the antibody response to GMMA persists and is likely to provide prolonged protection for those who need it. These results help show how antibody responses to bacterial antigens develop and how vaccines like GMMA can work and help prevent infection.